<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE301nnn/GSE301433/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Macaca mulatta</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301433</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>BCL-2 Inhibition at antiretroviral therapy initiation reduces the intact SIV reservoir in macaques</name><description>The anti-apoptotic molecule BCL-2 favors the maintenance of the CD4+ T-cell reservoir during Human immunodeficiency virus (HIV) infection. We investigated directly in-vivo whether BCL-2 inhibition using venetoclax at the initiation of antiretroviral therapy (ART) would reduce the size of the viral reservoir. Twenty-four SIVmac239-infected rhesus macaques (RMs) were initiated on ART at day 14 post-infection (p.i.), alone or in combination with either 10-day treatment with venetoclax or venetoclax plus CD8α depletion, and followed up to day 294 p.i. A rapid, statistically significant, and sustained reduction in the intact SIV reservoir was observed in venetoclax-treated RMs in blood and lymph nodes (LNs). This reduction was driven by reduced survival and depletion of CD4+ T-cell subsets that critically contribute to the reservoir. CD4+ T-cells that persisted after venetoclax treatment exhibited elevated per-cell levels of BCL-2, reduced expression of pro-apoptotic molecules such as PUMA, increased expression of additional anti-apoptotic molecules, including BCL-xL, and a partial reduction in apoptotic sensitivity in ex vivo assays. These findings provide mechanistic insights for the venetoclax-induced pro-cell death changes in CD4+ T-cells, support the rationale for extended venetoclax dosing, and suggest that combining BCL-2 inhibition with agents targeting additional anti-apoptotic molecules can enhance clearance of the viral reservoir in HIV cure strategies.</description><dates><publication>2026/06/28</publication></dates><accession>GSE301433</accession><cross_references><GSM>GSM9083235</GSM><GSM>GSM9083224</GSM><GSM>GSM9083234</GSM><GSM>GSM9083223</GSM><GSM>GSM9083237</GSM><GSM>GSM9083226</GSM><GSM>GSM9083215</GSM><GSM>GSM9083236</GSM><GSM>GSM9083225</GSM><GSM>GSM9083217</GSM><GSM>GSM9083228</GSM><GSM>GSM9083227</GSM><GSM>GSM9083216</GSM><GSM>GSM9083219</GSM><GSM>GSM9083229</GSM><GSM>GSM9083218</GSM><GSM>GSM9083220</GSM><GSM>GSM9083231</GSM><GSM>GSM9083230</GSM><GSM>GSM9083233</GSM><GSM>GSM9083222</GSM><GSM>GSM9083232</GSM><GSM>GSM9083221</GSM><GPL>27943</GPL><GSE>301433</GSE><taxon>Macaca mulatta</taxon></cross_references></HashMap>